Os01g0140700 Antibody

What is Os01g0140700 and why is it important in rice immunity research?

Os01g0140700 encodes the OsERF101 (also known as OsRAP2.6) transcription factor, a member of the AP2/ERF-type family of transcription factors in rice. This protein has significant importance in plant immunity as it interacts with the nucleotide-binding leucine-rich repeat receptor (NLR) Xa1, which recognizes transcription activator-like (TAL) effectors from the rice pathogen Xanthomonas oryzae pv oryzae (Xoo) . OsERF101 functions in the nucleus as part of the immune recognition complex and regulates genes involved in response to stimulus. Research has shown that OsERF101 can function as both a positive regulator of Xa1-mediated immunity and also negatively regulates an additional Xa1-mediated immune pathway . Understanding this protein is crucial for unraveling the molecular mechanisms of rice immunity against bacterial leaf blight, one of the most economically important rice diseases worldwide.

What are the key structural features of the Os01g0140700-encoded protein that an antibody might target?

The OsERF101 protein contains an AP2/ERF domain, which is a plant-specific DNA-binding domain that enables transcription factor activity. When designing or selecting an antibody against this protein, researchers should consider targeting unique epitopes rather than the highly conserved AP2/ERF domain, which may lead to cross-reactivity with other AP2/ERF family members. The protein also interacts with both Xa1 (via its BED domain) and TAL effectors in the nucleus , suggesting that it contains interaction domains that could potentially be affected by antibody binding. Understanding the full protein structure, including post-translational modifications that might occur during immune activation, is essential for effective antibody selection and experimental design.

How should I validate an Os01g0140700 antibody before using it in my experiments?

Validating antibodies is a critical step that is often overlooked in research, leading to irreproducible results. For Os01g0140700 antibody validation, a multi-step approach is recommended. First, perform western blot analysis using both wild-type rice tissues and tissues from an oserf101 knockout mutant generated using CRISPR/Cas9 . A genuine antibody should show a band of the expected molecular weight in wild-type samples but not in the knockout samples. Second, conduct immunoprecipitation followed by mass spectrometry to confirm that the antibody captures the intended target. Third, test the antibody in multiple applications (immunoblotting, immunofluorescence, etc.) to determine its application-specific performance . Recombinant expression of the target protein can provide a positive control, while utilizing tissues where the target is known to be upregulated (e.g., following pathogen challenge) can help verify specificity . Remember that antibodies may not perform identically across different applications, and validation should be conducted for each intended use.

What are the optimal experimental conditions for using Os01g0140700 antibody in immunoblotting?

For immunoblotting applications with Os01g0140700 antibody, researchers should extract total proteins from rice tissues using a buffer containing 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, and a protease inhibitor cocktail . When working with rice protoplasts or whole tissues, it's important to optimize protein extraction conditions to ensure complete solubilization of the transcription factor, which may be present at relatively low abundance and primarily in the nucleus. For SDS-PAGE separation, use 10-12% gels for optimal resolution of the OsERF101 protein. After transfer to a membrane, block with 5% non-fat dry milk or BSA in TBST buffer for 1 hour at room temperature, and then incubate with the primary antibody at a validated dilution (typically 1:1000 to 1:5000) overnight at 4°C. Following washing steps, use an appropriate secondary antibody conjugated to HRP or a fluorescent tag for detection. Include positive controls (overexpression lines) and negative controls (knockout mutants) in each experiment to validate specificity.

How can I use Os01g0140700 antibody for subcellular localization studies?

For subcellular localization studies, immunofluorescence techniques can be employed with the Os01g0140700 antibody. Rice protoplasts are an excellent system for this purpose, as they allow for easy visualization of subcellular compartments. Isolate protoplasts from cultured rice cells using Cellulase RS and Macerozyme R-10 as described previously . Fix the protoplasts with 4% paraformaldehyde, permeabilize with a gentle detergent, and block with appropriate blocking buffer before incubating with the primary Os01g0140700 antibody. Use a fluorophore-conjugated secondary antibody for detection. Nuclear counterstaining with DAPI will help confirm the expected nuclear localization of OsERF101. Alternatively, conduct co-localization studies with known nuclear markers. For in vivo studies, consider using GFP-tagged OsERF101 to complement the antibody-based approach . Fluorescence microscopy with the ApoTome2 system provides excellent resolution for visualizing nuclear localization patterns. Always include controls to confirm specificity, such as pre-immune serum controls and peptide competition assays.

What is the best approach for using Os01g0140700 antibody in co-immunoprecipitation studies to identify interaction partners?

Co-immunoprecipitation (Co-IP) is particularly valuable for studying OsERF101 given its role in protein-protein interactions with both Xa1 and TAL effectors. For optimal results, perform protein extraction from rice tissues in non-denaturing conditions using a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, and protease inhibitors. Pre-clear the lysate with protein A/G beads before incubating with the Os01g0140700 antibody overnight at 4°C. Use protein A/G beads to capture the antibody-protein complexes, wash thoroughly to remove non-specific interactions, and elute bound proteins for subsequent analysis by SDS-PAGE and immunoblotting or mass spectrometry. Confirm interactions with specific proteins (e.g., Xa1 and TAL effectors) using reverse Co-IP with antibodies against the suspected interaction partners . Alternatively, bimolecular fluorescence complementation (BiFC) assays in rice protoplasts can provide complementary evidence for protein-protein interactions, as demonstrated for OsERF101 interactions . Always include appropriate negative controls such as IgG controls and samples from knockout lines to validate specific interactions.

How can I use Os01g0140700 antibody to study dynamic changes in protein expression during pathogen infection?

Studying the dynamics of OsERF101 expression during pathogen infection requires a combination of techniques. Using the Os01g0140700 antibody, perform time-course experiments by collecting samples at different time points after inoculation with Xoo. Extract proteins and analyze by immunoblotting to detect changes in OsERF101 protein levels. Complement this with qRT-PCR to correlate protein changes with transcript levels . To gain spatial information, perform immunohistochemistry on leaf sections using the validated antibody to visualize tissue-specific changes in expression. For quantitative assessment, consider developing an ELISA protocol specific for OsERF101. When interpreting results, be mindful that changes in protein levels may not directly correlate with transcript levels due to post-transcriptional regulation mechanisms. Additionally, analyze OsERF101 expression in both compatible and incompatible interactions with different Xoo strains (e.g., T7174 and T7133) to understand differential responses. Include appropriate controls in each experiment, such as mock-inoculated plants and references to constitutively expressed proteins, to normalize for loading variations.

What approaches can I use to investigate OsERF101 post-translational modifications during immune responses?

Investigating post-translational modifications (PTMs) of OsERF101 during immune responses requires specialized techniques beyond basic immunoblotting. First, use phospho-specific antibodies if available, or general phospho-serine/threonine antibodies after immunoprecipitation with the Os01g0140700 antibody. Alternatively, perform Phos-tag SDS-PAGE followed by immunoblotting with the Os01g0140700 antibody to detect mobility shifts indicative of phosphorylation. For comprehensive PTM mapping, immunoprecipitate OsERF101 from both control and pathogen-challenged tissues using the validated antibody, followed by mass spectrometry analysis. Compare PTM profiles between samples to identify infection-induced modifications. To connect PTMs with functional outcomes, use site-directed mutagenesis to create phospho-mimetic or phospho-dead variants of OsERF101, and express these in the oserf101 knockout background to assess their impact on immunity. For studying ubiquitination, perform immunoprecipitation under denaturing conditions followed by immunoblotting with anti-ubiquitin antibodies. These approaches will provide insights into how PTMs regulate OsERF101 function during immune responses.

How can I use chromatin immunoprecipitation (ChIP) with Os01g0140700 antibody to identify direct target genes?

Chromatin immunoprecipitation (ChIP) with the Os01g0140700 antibody can reveal the genomic loci directly bound by OsERF101. Begin by cross-linking proteins to DNA in intact rice tissues or protoplasts using formaldehyde. Lyse cells and sonicate chromatin to fragments of approximately 200-500 bp. Immunoprecipitate chromatin fragments using the validated Os01g0140700 antibody, with IgG as a negative control and input chromatin as a reference. After reverse cross-linking and DNA purification, analyze enriched DNA fragments through ChIP-qPCR for known targets or ChIP-seq for genome-wide binding site identification. To enhance specificity, perform ChIP in both wild-type and oserf101 knockout plants , where signal should be absent in the knockout. For functional validation of identified targets, correlate ChIP data with RNA-seq data from OsERF101-overexpressing and knockout lines . Focus particularly on genes involved in "regulation of response to stimulus," which were shown to be differentially regulated in OsERF101 transgenic lines . This approach will establish the direct transcriptional regulatory network controlled by OsERF101 during immune responses.

I'm getting inconsistent results with my Os01g0140700 antibody. What could be the problem and how can I address it?

Inconsistent results with Os01g0140700 antibody could stem from several factors. First, consider antibody quality and batch variation, a common issue with research antibodies . Request datasheet information about validation methods used by the manufacturer and perform your own validation using positive controls (OsERF101-overexpressing lines) and negative controls (oserf101 knockout mutants) . Second, examine experimental conditions: buffer composition, protein extraction method, incubation times, and washing steps can all affect antibody performance. Third, verify target protein expression levels in your samples, as OsERF101 expression may vary with experimental conditions, tissue types, and developmental stages. Fourth, assess protein stability during extraction by adding fresh protease inhibitors and keeping samples cold. Fifth, consider post-translational modifications that might affect epitope recognition. If problems persist, try alternative antibody clones or lots, or consider generating your own antibody against a unique epitope. For western blotting specifically, optimize protein loading, transfer conditions, and blocking buffers. Remember that antibody performance is application-dependent, and validation in one application does not guarantee performance in another .

What are the most common pitfalls when interpreting data from experiments using Os01g0140700 antibody?

Interpreting data from experiments using Os01g0140700 antibody requires careful consideration of several potential pitfalls. First, beware of non-specific binding, which can lead to false positive signals. Always include appropriate negative controls (oserf101 knockout) to distinguish specific from non-specific signals . Second, consider cross-reactivity with other AP2/ERF family members, which share sequence similarity with OsERF101. Third, be cautious about inferring protein function solely from localization or interaction data; functional studies with genetic knockouts or overexpression lines are necessary to establish causality . Fourth, remember that antibody binding may interfere with protein function or interactions, potentially affecting results in functional assays. Fifth, be mindful that OsERF101 may exist in different isoforms or modified states that affect antibody recognition. Sixth, consider the quantitative limitations of immunoblotting and immunofluorescence when making comparisons between samples. Finally, avoid overinterpreting correlative data without mechanistic validation. To enhance data reliability, combine antibody-based approaches with complementary techniques such as genetic studies, reporter assays, and direct protein analysis methods .

How can I distinguish between specific and non-specific signals when using Os01g0140700 antibody?

Distinguishing between specific and non-specific signals is crucial for accurate data interpretation. First, always include both positive controls (OsERF101-overexpressing lines) and negative controls (oserf101 knockout mutants) in parallel with your experimental samples. A specific signal should be present in wild-type and overexpression samples but absent in knockout samples. Second, perform peptide competition assays by pre-incubating the antibody with excess immunizing peptide; specific signals should be blocked in these conditions. Third, compare the observed molecular weight of detected bands with the predicted weight of OsERF101. Fourth, confirm specificity using an independent antibody raised against a different epitope of the same protein; concordant results strengthen confidence in specificity. Fifth, validate results using orthogonal methods, such as mass spectrometry identification of immunoprecipitated proteins. Sixth, assess signal patterns across different tissues or conditions where OsERF101 expression is known to vary. For immunofluorescence applications, include secondary antibody-only controls and pre-immune serum controls to identify background fluorescence. Finally, consider using tagged versions of OsERF101 (e.g., HA-tag) as an alternative approach when antibody specificity is questionable.

What minimum validation data should I include when publishing research using Os01g0140700 antibody?

When publishing research using Os01g0140700 antibody, include comprehensive validation data to ensure reproducibility . First, provide complete antibody information: supplier, catalog number, clone or lot number, dilution used, and validation method references. Second, include images of full immunoblots with molecular weight markers, not just cropped relevant bands. Third, present both positive controls (OsERF101-overexpressing lines) and negative controls (oserf101 knockout mutants) to demonstrate specificity. Fourth, describe all experimental conditions in detail, including buffer compositions, incubation times, and washing procedures. Fifth, report any optimization steps undertaken to improve antibody performance. Sixth, include validation data specific to each application used (e.g., immunoblotting, immunofluorescence, ChIP), as performance may vary across applications . Seventh, acknowledge any limitations observed with the antibody. Ideally, verify key findings with an independent antibody or orthogonal method. Following these practices addresses the "technical, data sharing, behavioral and policy challenge" identified in improving antibody research integrity and allows other researchers to accurately replicate your work.